The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Sep. 25, 2020
Applicant:

Celgene Quanticel Research, Inc., San Diego, CA (US);

Inventors:

Robert Cho, Sunnyvale, CA (US);

Jeffrey Alan Stafford, San Diego, CA (US);

Assignee:

Celgene Quanticel Research, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/472 (2006.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/495 (2006.01); A61K 38/15 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/472 (2013.01); A61K 31/337 (2013.01); A61K 31/495 (2013.01); A61K 38/15 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2300/00 (2013.01);
Abstract

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.


Find Patent Forward Citations

Loading…